Tags

Type your tag names separated by a space and hit enter

[Secondary hyperparathyroidism--risk factor for development of cardiovascular complications in patients on hemodialysis].
Med Pregl 2010 Sep-Oct; 63(9-10):674-80MP

Abstract

INTRODUCTION Cardiovascular disease is a leading cause of death among hemodialysis patients.

SECONDARY HYPERPARATHYROIDISM

Secondary hyperparathyroidism is one of the main factors for the development of cardiovascular complications among these patients. A high concentration of parathormone, hypercalcemia, hyperphosphatemia and high calcium x phosphate product among dialysis patients play a crucial role in the development of vascular (calcification of coronary artery) and valvular calcifications. DISCUSSION AND CONCLUSION With every new patient on hemodialysis it is necessary to see if there is a vascular/valvular calcification in order to single out the patients at risk of progression of coronary artery calcification and to use non-calcium containing binder phosphate in due time. Non-calcium containing binder phosphate, new active vitamin D agents and calcimimetics prevent the development of secondary hyperparathyroidism as well as cardiovascular complications and decrease the rate of cardiovascular morbidity and mortality of these patients.

Authors+Show Affiliations

Klinicki centar Kragujevac, Kragujevac. aca96@eunet.rsNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

srp

PubMed ID

21446098

Citation

Petrović, Dejan, and Biljana Stojimirović. "[Secondary Hyperparathyroidism--risk Factor for Development of Cardiovascular Complications in Patients On Hemodialysis]." Medicinski Pregled, vol. 63, no. 9-10, 2010, pp. 674-80.
Petrović D, Stojimirović B. [Secondary hyperparathyroidism--risk factor for development of cardiovascular complications in patients on hemodialysis]. Med Pregl. 2010;63(9-10):674-80.
Petrović, D., & Stojimirović, B. (2010). [Secondary hyperparathyroidism--risk factor for development of cardiovascular complications in patients on hemodialysis]. Medicinski Pregled, 63(9-10), pp. 674-80.
Petrović D, Stojimirović B. [Secondary Hyperparathyroidism--risk Factor for Development of Cardiovascular Complications in Patients On Hemodialysis]. Med Pregl. 2010;63(9-10):674-80. PubMed PMID: 21446098.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Secondary hyperparathyroidism--risk factor for development of cardiovascular complications in patients on hemodialysis]. AU - Petrović,Dejan, AU - Stojimirović,Biljana, PY - 2011/3/31/entrez PY - 2011/3/31/pubmed PY - 2011/4/29/medline SP - 674 EP - 80 JF - Medicinski pregled JO - Med. Pregl. VL - 63 IS - 9-10 N2 - UNLABELLED: INTRODUCTION Cardiovascular disease is a leading cause of death among hemodialysis patients. SECONDARY HYPERPARATHYROIDISM: Secondary hyperparathyroidism is one of the main factors for the development of cardiovascular complications among these patients. A high concentration of parathormone, hypercalcemia, hyperphosphatemia and high calcium x phosphate product among dialysis patients play a crucial role in the development of vascular (calcification of coronary artery) and valvular calcifications. DISCUSSION AND CONCLUSION With every new patient on hemodialysis it is necessary to see if there is a vascular/valvular calcification in order to single out the patients at risk of progression of coronary artery calcification and to use non-calcium containing binder phosphate in due time. Non-calcium containing binder phosphate, new active vitamin D agents and calcimimetics prevent the development of secondary hyperparathyroidism as well as cardiovascular complications and decrease the rate of cardiovascular morbidity and mortality of these patients. SN - 0025-8105 UR - https://www.unboundmedicine.com/medline/citation/21446098/[Secondary_hyperparathyroidism__risk_factor_for_development_of_cardiovascular_complications_in_patients_on_hemodialysis]_ L2 - https://medlineplus.gov/dialysis.html DB - PRIME DP - Unbound Medicine ER -